CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES >

2025 , Vol. 43 >Issue 5: 718 - 722

DOI: https://doi.org/10.12140/j.issn.1000-7423.2025.05.018

REVIEWS

Current status and research progress of triclabendazole resistance in fascioliasis treatment

  • CHEN Chong ,
  • ZHU Aihong ,
  • HUANG Qin
Expand
  • Department of Infectious Diseases, Shanghai Public Health Clinical Center, Shanghai 201508, China

Received date: 2025-02-13

  Revised date: 2025-06-07

  Online published: 2025-08-27

Supported by

Shanghai Public Health Clinical Center Research Project(KY-GW-2022-20)

Fold

Abstract

Fascioliasis, which caused by Fasciola hepatica and F. gigantica, is a zoonotic parasitic disease that not only affects human health but also poses a serious threat to other mammals, especially herbivores. Triclabendazole (TCBZ) is the first choice for fascioliasis treatment. However, economic data monitoring in health care indicates that the threat of TCBZ resistance has brought challenges to the health of animals in endemic areas and caused huge economic losses. At the same time, clinical reports have also documented treatment failures possibly related to TCBZ resistance, posing risks to the prevention and control of fascioliasis. This article focuses on the current situation of TCBZ treatment failure and/or resistance in fascioliasis, risk factors for TCBZ resistance, resistance mechanisms, progress in new drug development and exploration of new treatment methods, with the aim of providing references for further research on the prevention and control of fascioliasis.

Key words： Fascioliasis; Triclabendazole; Drug resistance; Research progress

Cite this article

CHEN Chong , ZHU Aihong , HUANG Qin . Current status and research progress of triclabendazole resistance in fascioliasis treatment[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2025 , 43(5) : 718 -722 . DOI: 10.12140/j.issn.1000-7423.2025.05.018

References

[1] Good R, Scherbak D. Fascioliasis[J/OL]. StatPearls. (2023-05-01)[2025-02-13]. https://www.ncbi.nlm.nih.gov/sites/books/NBK537032/.
[2] 姚嘉文, 贾铁武. 片形吸虫的全球分布及传播[J]. 中国血吸虫病防治杂志, 2022, 34(6): 654-658.
  Yao JW, Jia TW. Global distribution and transmission of Fasciola[J]. Chin J Schisto Control, 2022, 34(6): 654-658. (in Chinese)
[3] Siles-Lucas M, Becerro-Recio D, Serrat J, et al. Fascioliasis and fasciolopsiasis: Current knowledge and future trends[J]. Res Vet Sci, 2021, 134: 27-35.
[4] Girma A, Genet A, Teshome K, et al. Prevalence and economic significance of fasciolosis among cattle slaughtered at municipal abattoirs in Ethiopia from 2010 to 2023: A systematic review and meta-analysis[J]. Vet Med Sci, 2025, 11(1): e70186.
[5] Mas-Coma S, Bargues MD, Valero MA. Fascioliasis and other plant-borne trematode zoonoses[J]. Int J Parasitol, 2005, 35(11/12): 1255-1278.
[6] Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites[J]. J Allergy Clin Immunol, 2004, 113(1): 30-37.
[7] Cwiklinski K, Jewhurst H, McVeigh P, et al. Infection by the helminth parasite Fasciola hepatica requires rapid regulation of metabolic, virulence, and invasive factors to adjust to its mammalian host[J]. Mol Cell Proteomics, 2018, 17(4): 792-809.
[8] 柏厚熹, 杨小涛, 罗永涵, 等. 儿童肝片形吸虫合并铜绿假单胞菌感染1例[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(4): 550-553.
  Bai HX, Yang XT, Luo YH, et al. A case of Fasciola hepatica infection combined with Pseudomonas aeruginosa in a child[J]. Chin J Parasitol Parasit Dis, 2024, 42(4): 550-553. (in Chinese)
[9] Lalor R, Cwiklinski K, Calvani NED, et al. Pathogenicity and virulence of the liver flukes Fasciola hepatica and Fasciola gigantica that cause the zoonosis fasciolosis[J]. Virulence, 2021, 12(1): 2839-2867.
[10] Tanabe MB, Caravedo MA, Clinton White A Jr, et al. An update on the pathogenesis of fascioliasis: What do we know?[J]. Res Rep Trop Med, 2024, 15: 13-24.
[11] 李素君, 白秋江. 三氯苯达唑: 治疗人片形吸虫病的有效药物[J]. 寄生虫与医学昆虫学报, 2020, 27(3): 184-188.
  Li SJ, Bai QJ. Triclabendazole: An effective drug for human fascioliasis therapy[J]. Acta Parasitol Med Entomol Sin, 2020, 27(3): 184-188. (in Chinese)
[12] Dauchy FA, Laharie D, Neau D, et al. Fascioliasis: A 23-year retrospective study[J]. Presse Med, 2007, 36(11 Pt 1): 1545-1549.
[13] El-Tantawy WH, Salem HF, Mohammed Safwat NAS. Effect of fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects[J]. Pharm World Sci, 2007, 29(3): 190-198.
[14] Morales ML, Tanabe MB, Clinton White A Jr, et al. Triclabendazole treatment failure for Fasciola hepatica infection among preschool and school-age children, Cusco, Peru[J]. Emerg Infect Dis, 2021, 27(7): 1850-1857.
[15] Terashima A, Canales M, Maco V, et al. Observational study on the effectiveness and safety of multiple regimens of triclabendazole in human fascioliasis after failure to standard-of-care regimens[J]. J Glob Antimicrob Resist, 2021, 25: 264-267.
[16] Lalrinkima H, Lalchhandama C, Jacob SS, et al. Fasciolosis in India: An overview[J]. Exp Parasitol, 2021, 222: 108066.
[17] Castro-Hermida JA, González-Warleta M, Martínez-Sernández V, et al. Current challenges for fasciolicide treatment in ruminant livestock[J]. Trends Parasitol, 2021, 37(5): 430-444.
[18] Kamaludeen J, Graham-Brown J, Stephens N, et al. Lack of efficacy of triclabendazole against Fasciola hepatica is present on sheep farms in three regions of England, and Wales[J]. Vet Rec, 2019, 184(16): 502.
[19] Kelley JM, Rathinasamy V, Elliott TP, et al. Determination of the prevalence and intensity of Fasciola hepatica infection in dairy cattle from six irrigation regions of Victoria, South-eastern Australia, further identifying significant triclabendazole resistance on three properties[J]. Vet Parasitol, 2020, 277: 109019.
[20] Larroza M, Aguilar M, Soler P, et al. Triclabendazole resistance in Fasciola hepatica: First report in sheep from the Santa Cruz Province, Argentinian Patagonia[J]. Vet Parasitol Reg Stud Reports, 2023, 45: 100927.
[21] Richter J, Freise S, Mull R, et al. Fascioliasis: Sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole[J]. Trop Med Int Health, 1999, 4(11): 774-781.
[22] Beesley NJ, Cwiklinski K, Allen K, et al. A major locus confers triclabendazole resistance in Fasciola hepatica and shows dominant inheritance[J]. PLoS Pathog, 2023, 19(1): e1011081.
[23] Marcos L, Maco V, Terashima A. Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures[J]. Expert Rev Anti Infect Ther, 2021, 19(7): 817-823.
[24] Mollinedo S, Gutierrez P, Azurduy R, et al. Mass drug administration of triclabendazole for Fasciola hepatica in Bolivia[J]. Am J Trop Med Hyg, 2019, 100(6): 1494-1497.
[25] Brennan GP, Fairweather I, Trudgett A, et al. Understanding triclabendazole resistance[J]. Exp Mol Pathol, 2007, 82(2): 104-109.
[26] Fairweather I. Raising the bar on reporting ‘triclabendazole resistance’[J]. Vet Rec, 2011, 168(19): 514-515.
[27] Mas-Coma S, Valero MA, Bargues MD. Fascioliasis[J]. Adv Exp Med Biol, 2019, 1154:71-103.
[28] Fairweather I, Brennan GP, Hanna RB, et al. Drug resistance in liver flukes[J]. Int J Parasitol Drugs Drug Resist, 2020, 12: 39-59.
[29] Fairweather I. Triclabendazole progress report, 2005-2009: An advancement of learning?[J]. J Helminthol, 2009, 83(2): 139-150.
[30] Fuchs MA, Ryan LA, Chambers EL, et al. Differential expression of liver fluke β-tubulin isotypes at selected life cycle stages[J]. Int J Parasitol, 2013, 43(14): 1133-1139.
[31] Meaney M, Allister J, McKinstry B, et al. Fasciola hepatica: Morphological effects of a combination of triclabendazole and clorsulon against mature fluke[J]. Parasitol Res, 2006, 99(5): 609-621.
[32] David MA, Orlowski S, Prichard RK, et al. In silico analysis of the binding of anthelmintics to Caenorhabditis elegans P-glycoprotein 1[J]. Int J Parasitol Drugs Drug Resist, 2016, 6(3): 299-313.
[33] Alvarez LI, Solana HD, Mottier ML, et al. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes[J]. Parasitology, 2005, 131(Pt 4): 501-510.
[34] Radio S, Fontenla S, Solana V, et al. Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs[J]. Parasit Vectors, 2018, 11(1): 56.
[35] Rinaldi G, Dell’Oca N, Castillo E, et al. Gene silencing in the liver fluke Fasciola hepatica: RNA interference[J]. Methods Mol Biol, 2020, 2137: 67-92.
[36] Cwiklinski K, Dalton JP. Advances in Fasciola hepatica research using ‘omics’ technologies[J]. Int J Parasitol, 2018, 48(5): 321-331.
[37] Lamb J, Doyle E, Barwick J, et al. Kangaroos and liver fluke: The role played in cross-species transmission and drug resistance[J]. Vet Parasitol, 2021, 300: 109589.
[38] Dauchy FA, Vincendeau P, Lifermann F. Eight cases of fascioliasis: Clinical and microbiological features[J]. Med Mal Infect, 2006, 36(1): 42-46.
[39] Cabada MM, Lopez M, Cruz M, et al. Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: A case series[J]. PLoS Negl Trop Dis, 2016, 10(1): e0004361.
[40] Gonzalez AE, Codd EE, Horton J, et al. Oxfendazole: A promising agent for the treatment and control of helminth infections in humans[J]. Expert Rev Anti Infect Ther, 2019, 17(1): 51-56.
[41] Zinsser VL, Hoey EM, Trudgett A, et al. Biochemical characterisation of triose phosphate isomerase from the liver fluke Fasciola hepatica[J]. Biochimie, 2013, 95(11): 2182-2189.
[42] Zinsser VL, Hoey EM, Trudgett A, et al. Biochemical characterisation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the liver fluke, Fasciola hepatica[J]. Biochim Biophys Acta BBA Proteins Proteom, 2014, 1844(4): 744-749.
[43] Ferraro F, Corvo I, Bergalli L, et al. Novel and selective inactivators of triosephosphate isomerase with anti-trematode activity[J]. Sci Rep, 2020, 10(1): 2587.
[44] Zárate-Rendón DA, Briones-Montero A, Huaraca-Oré NA, et al. Comparison of the therapeutic efficacy of five anthelmintics against natural Fasciola hepatica infections in dairy cattle from the Mantaro Valley, Peru[J]. Vet Parasitol Reg Stud Reports, 2023, 38: 100827.
[45] Hasan MM, Roy BC, Biswas H, et al. Efficacy of flukicides on Fasciola gigantica, a food-borne zoonotic helminth affecting livestock in Bangladesh[J]. Parasitology, 2022, 149(10): 1339-1348.
[46] Rehman A, Ullah R, Gupta D, et al. Generation of oxidative stress and induction of apoptotic like events in curcumin and thymoquinone treated adult Fasciola gigantica worms[J]. Exp Parasitol, 2020, 209: 107810.
[47] Chakroborty A, Pritchard D, Bouillon ME, et al. Flukicidal effects of abietane diterpenoid derived analogues against the food borne pathogen Fasciola hepatica[J]. Vet Parasitol, 2022, 309: 109766.
Options
Outlines

/

〈 〉